Insulin-like growth factors: the unrecognised oncogenes. by Westley, B. R. & May, F. E.
B_h JummiI iCi (285)72,1065-1066
© 1995 ockkm Press Alrg rserved0007-0920/95 $12.00 S
GUEST EDITORIAL
Insulin-like growth factors: the unrecognised oncogenes
BR Westley and FEB May
Department ofPathology, Royal Victoria Infirmry, Newcastle upon Tyne NE) 4LP, UK.
The identification of genes involved in the transformation of
cells proceeded rapidly during the 1970s and 1980s from the
analysis of oncogenic retroviruses and the identification of
oncogenes using DNA transfection techniques. Although
many important genes were isolated, it was unlkely that
these methods alone would identify all transforming genes.
This commentary briefly reviews recent studies, inchluding one
published in this issue of the Britih Journal of Cancer from
the laboratory of Dr CF Graham (Oxford, UK; see Bates et
al., 1995), which implicate components of the insulin-like
growth factor (IGF) signal transduction pathway in the
malignant transformation of cells.
Insulin-like growth factors (IGF-I and IGF-H) are
involved in controlling normal growth and development and
IGF-I in particula is involved in mediating the effects of
growth hormone. They are thought to control cell growth
and cell division pincipally through the type I IGF receptor,
a heterotetrameic receptor located on the cell surface that
has a similar structure to the insulin receptor. IGFs, but not
insulin, also bind to a family of proteins called the IGF-
binding proteins (IGFBPs) and the majority of IGFs in the
circulation are present as a complex with IGFBP-3. Six
IGFBPs have been described to date and although their
function is not totally clear, they are generally thought to
modulate the biological activity of IGFs.
There has been increasing recognition during the past 5
years of the role of IGFs, type I IGF receptor and IGFBPs
in the control of the proliferation of cancer cells. IGFs are
potent mitogens for a wide variety of tumour cell types and
have been identified as major autocrine or paracrne growth
factors in a number of cancrs (Daughaday, 1990; Macauley,
1994). IGFs have also been implicated as mediators of the
effects of steroids on the proliferation of hormone-responsive
cancers, such as breast cancer (Westley and May, 1994). In
addition, there has been some suggestion of the importance
of circulating IGF levels on tumour growth and reports that
therapeutic strategies may influence tumour cell growth by
lowering circulating IGF levels (Pollak et al., 1990).
Most experments to date have focused on the importance
of IGFs in controlling the proliferation of previously trans-
formed cells, however, evidence is now starting to accumulate
that components of the IGF signal transduction system may
play a role in the transformation process itself. The article by
Bates et al. (1995) in this issue of the British Journal of
Cancer contributes significntly to this debate by demons-
trating that transgenc mie, in which expresson of insun-
like growth factor II (IGF-II) was targeted to the mammary
gland by plaing it under the control of the sheep P-
lactoglobulin promoter, develop an excess of mammary
tumours.
The same group (Ward et al., 1994) had previously made
IGF-H tansgenic mice, in which the IGF-H gene had been
placed under the control of a keratin promoter that resut
in elevated expression in skin, alimentary canal and uterus.
Growth effects were observed in these organs, but no
tumours formed in animals up to 9 months of age- Rogler et
al. (1994) made transgenic mice in which IGF-ll expression
was targeted to the liver under the control of the major
urinary protein promoter. In this case, mice developed
diverse tumours with a preponderance of heptocellular car-
cinoma. The studies of Bates et al. (1995) and Rogler et al.
(1994) are therefore in broad agreement and are the first in
vivo experiments to suggest a direct role for IGFs in the
malignant transformation of cells.
Although neither the IGFs nor the type I IGF receptor
had been identified as oncogenes from the analysis of
oncogenic viruses or by cell transformation assays, earlier
stuies (Kaleko et al., 1990) had suggested that the type I
IGF receptor could act as a transforming gene when overex-
pressed in NIH 3T3 cells. Interetingly, these eexperiments
used the normal receptor and transformation was ligand
dependent Tlhis contrasts with tansformation by other cel-
lular oncogenes, for example the erbB/EGF receptor in
which the ligand binding domain of the oncogenic form is
deleted.
Evidence for the involvement of the IGF signal transduc-
tion pathway in cell transformation has also come from other
avenues of research.
Prager et al. (1994) transfected cells with wild-type and a
truncated a-subunit mutant of the type I IGF receptor (trun-
cated at amino acid 952 to abolish tyrosine kinase activity).
Cells overexpressing wild-type receptor showed increased
ligand-dependent transformation. In contrast, cells trans-
fected with truncated receptor were completely non-
responsive to IGF-1, were unable to sustain anchorage-
independent growth and did not form tumours in nude mice
- these latter two features being characteristics of trans-
formed cells. The truncated receptor therefore appeared to
behave as a dominant negative inhibitor of endogenous type
I IGF receptor and again emphasised the importance of this
receptor in maintaining the transformed phenotype.
Two studies have shown that the IGF signal transduction
pathway is involved in the transformation of cells by other
oncogenes.
Studies on the mechnism by which the src oncogene
transforms cells have identified the type I IGF receptor as a
functionally significant substrate for pp60' (Peterson et al.,
1994). Tyrosine phosphorylation of the type I IGF receptor
correlates with cell transformation using a panel of partially
defective src mutants. Phosphorylation of type I IGF recep-
tor by src increases receptor tyrosine kinase activity both
towards itself and exogenous substrates and these
experiments are therefore consistent with the type I IGF
receptor acting as an intermediary in the transformation of
cells by src. ,
Christofori et al. (1994), studied -the induction of pan-
creatic tumours in transgenic mice expresng the sinuan
virus-4 large T antigen under the control of the insulin gene
regulatory region. In this system a high proportion of the
islets become hyperplastic and vascularisation kads to
tumours in 1-2% of islets. A survey of the expression of
growth factors, receptors and oncogenes showed that IGF-fl
expression is focally activated in a subset of islets and is
further up-regulated in all tumours. This study concluded
that IGF-H provides an important second signal in eliciting
the hyperproliferation, which eventually leads to tumour for-
mation.
There are, therefore, several lines of evidence showing that
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the type I IGF receptor can act as a ligand-dependent
oncogene and that expression of IGFs is important in
tumorigenesis. Is there any epidemiological evidence or
clinical studies that might suggest that individuals with local
or systemic elevated IGF levels are at an increased risk of
cancer?
Stoll (1993) has recently reviewed the evidence that cir-
culating levels of insulin and insulin-like growth factors are
risk markers for breast cancer. Case-control studies have
reported increased serum insulin (Bruning et al., 1992) and
plasma IGF-I (Peyrat et al.. 1993) in women presenting with
breast cancer. Increased circulating levels of insulin and IGF-
I may be linked to other recognised risk markers for breast
cancer including early onset of menarche. relative tallness
and upper body type of obesity. Earlier onset of pubertal
hyperinsulinaemia may be involved in earlier onset of
ovulatory cycles because IGFs increase the effect of FSH in
stimulating ovarian steroid synthesis (Garzo and Dorrington.
1984). Prospective studies (e.g. De Waard, 1975; London et
al., 1989; Tretll. 1989) have reported an association between
tallness and breast cancer risk. There is also an increased risk
of breast cancer in women with upper (male type) obesity
associated with high insulin levels (Schapira et al., 1990;
Conover et al.. 1992).
The analysis of patients with acromegaly. a condition in
which IGF-I levels are elevated as a result of increased
secretion of growth hormone, may provide evidence for an
increased risk of cancer from elevated IGF levels. Interest-
ingly, Klein et al. (1982) showed a signficantly increased
frequency of colonic polyps (frequently regarded as premalig-
nant lesions) in patients with acromegaly and has suggested
that this group of patients may have increased rates of colon
cancer.
Is there any risk that the population at large is being
systematically exposed to elevated levels of IGFs or that
IGFs could be environmental carcinogens? Diet has been
implicated in cancer risk and the association between tallness
and breast cancer risk for example could reflect the increases
in IGF-I levels in well-nourished individuals. Particular diets,
however. may be rich in IGFs. IGFs are present in milk.
being highest immediately post-partum and then decreasing
gradually thereafter. Dairy products are therefore a potential
dietary source of IGFs and these levels are higher in milk
from cows treated with bovine somatomammotrophin (BST)
to increase milk yield. Reassuringly. however. IGFs appear
to be destroyed in the gastrointestinal tract and there is no
evidence to suggest that the peculiarly human habit of inges-
ting milk in adulthood results in elevated systemic IGF levels
(Juskevich and Guyer. 1990). It is however a formal pos-
sibility that ingested IGFs in dairy products could have a
luminal site of action and the relationship between a diet rich
in dairy products and cancers of the gastrointestinal tract
could be of interest.
Although the evidence that components of the IGF signal
transduction system can be involved in cell transformation is
compelling. the mechanisms involved are not known. IGFs
have been shown to inhibit the effect of myc on apoptosis
(Harrington et al.. 1994) and Bates et al. (1995) suggest that
the principle function of IGF-II is to increase cell survival
thereby allowing somatic mutations to accumulate in other
oncogenes. The studies of Prager et al. (1994) and Peterson et
al. (1994) however are consistent with a more active role and
suggest that the IGF growth factor signal transduction
system itself could be responsible for increased proliferation
and the malignant transformation of cells.
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